Establishment and characterization of a novel lymphangiosarcoma cell line (MO‐LAS) compared with the hemangiosarcoma cell line (ISO‐HAS)

Cancer Medicine

Mikio Masuzawa²  Mamiko Masuzawa¹  Yuhko Hamada¹  Nobuko Arakawa¹  Mari Mori¹  Masako Ishii¹ 

[1] Department of Dermatology, Kitasato University School of Medicine, Sagamihara, Japan;Department of Regulation Biochemistry, Kitasato University School of Allied Sciences, Sagamihara, Japan

关键词: Cell line;    hemangiosarcoma;    lymphangiosarcoma;    PROX1;   

DOI  :  10.1002/cam4.12

来源: Wiley

【 摘 要 】

Abstract

The concept of “lymphangiosarcoma” remains obscure. Therefore, we reported a patient with lymphangiosarcoma, resistant to immunotherapy. The patient presented with impressive and discriminative features: clinically an ill-defined edematous lesion with lymphorrhea and pathologically atypical vascular channel formation without extravasation of blood, clearly distinguished from common angiosarcoma with hemorrhage. From this case, a lymphangiosarcoma cell line, MO-LAS, was established and its characteristics were compared with the hemangiosarcoma cell line, ISO-HAS. Flow cytometric analysis revealed that MO-LAS was negative for factor VIII-related antigen, but positive for CD31, D2-40, NZ-1, and vascular endothelial growth factor receptor-3 (VEGFR-3), similar to ISO-HAS. However, MO-LAS expressed a much higher level of homeobox gene PROX1, indicating a lymphatic phenotype, compared with ISO-HAS. Furthermore, MO-LAS showed a much lesser expression of oncogenes and much lower sensitivity against lymphokine-activated killer (LAK) cells. Lymphangiosarcoma may be difficult to recognize by the immune system. Conclusively, the establishment of MO-LAS, a novel angiosarcoma cell line bearing lymphatic characters, strongly suggests the entity of lymphangiosarcoma.

【 授权许可】

CC BY-NC   
© 2012 The Authors. Cancer Medicine published by Blackwell Publishing Ltd.

Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.